RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for … Read more
RemeGen Co. Ltd (REGMF) - Total Assets
Latest total assets as of September 2025: $5.97 Billion USD
Based on the latest financial reports, RemeGen Co. Ltd (REGMF) holds total assets worth $5.97 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
RemeGen Co. Ltd - Total Assets Trend (2018–2024)
This chart illustrates how RemeGen Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
RemeGen Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
RemeGen Co. Ltd's total assets of $5.97 Billion consist of 41.6% current assets and 58.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.8% |
| Accounts Receivable | $623.53 Million | 11.3% |
| Inventory | $659.37 Million | 12.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $143.13 Million | 2.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how RemeGen Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RemeGen Co. Ltd's current assets represent 41.6% of total assets in 2024, an increase from 12.2% in 2018.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2024, up from 1.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 12.0% of total assets.
RemeGen Co. Ltd Competitors by Total Assets
Key competitors of RemeGen Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
RemeGen Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - RemeGen Co. Ltd generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - RemeGen Co. Ltd is currently not profitable relative to its asset base.
RemeGen Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 1.36 | 6.90 |
| Quick Ratio | 0.73 | 0.96 | 6.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-114.00 Million | $ 663.22 Million | $ 2.55 Billion |
RemeGen Co. Ltd - Advanced Valuation Insights
This section examines the relationship between RemeGen Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.55 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | $5.50 Billion |
| Market Capitalization | $501.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values RemeGen Co. Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: RemeGen Co. Ltd's assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for RemeGen Co. Ltd (2018–2024)
The table below shows the annual total assets of RemeGen Co. Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.50 Billion | -0.54% |
| 2023-12-31 | $5.53 Billion | -8.19% |
| 2022-12-31 | $6.02 Billion | +44.77% |
| 2021-12-31 | $4.16 Billion | +1.01% |
| 2020-12-31 | $4.12 Billion | +497.36% |
| 2019-12-31 | $689.31 Million | +29.79% |
| 2018-12-31 | $531.09 Million | -- |